AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
A gene-expression profiling technique that yields a "fingerprint" of genetic activity in tissue samples can distinguish among breast cancers that arise from BRCA1, BRCA2, and sporadic gene mutations, according to investigators at the National Human Genome Research Institute, Bethesda, Md.
This finding has an immediate payoff of allowing more accurate classification of breast cancers, as well as the potential benefit of enabling researchers to design more targeted therapies for breast as well as other cancers, according to Dr. Ingrid Hedenfalk and her associates (N. Engl. J. Med. 344[8]:539-48, 2001).
The research, which used a DNA chip called a microarray to simultaneously assess the activity of more than 5,000 genes in tumor samples, also adds to the overall understanding of how breast cancers develop.
How quickly this technology will be adapted to routine clinical practice remains to be seen. In an editorial accompanying the report, Dr. Todd Golub of Harvard Medical School, Boston, said that the complexity and high cost of microarray technology are easily surmountable" barriers. "Rather, the main roadblock is the time that will be required to perform the requisite carefully controlled, large-scale studies to confirm these findings" (N. Engl. J. Med. 344[8]:601-02, 2001).
Source: HighBeam Research, Test IDs Cancers From BRCA1, BRCA2, Sporadic Mutations.